Trodelvy gets one up on Datroway in triple-negative breast
Gilead’s TROP2 ADC prevails in Ascent-04, in first-line PD-L1-positive TNBC.
RemeGen cools on DR5
A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
Telix sees more backing for LAT1
TLX101 follows Ipax-1 with an apparent success in an academic trial.
Mural hits a wall
The company scraps nemvaleukin after the latest failure, of Artistry-6.
Crispr’s Car-T crunch time
The group could soon provide clarity on CTX112’s regulatory path.
Another false dawn for p53
Boehringer discontinues brigimadlin while others continue to struggle.
BeiGene bows out of TIGIT
AstraZeneca and GSK/iTeos's odysseys get a little lonelier still.
Lilly’s big Jaypirca test approaches
After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.
